Skip to content
Clinical Trial Events
ISPOR Europe 2026

Panel Expanded Value Measures track

Whole Health at Risk: Does EU Joint Clinical Assessment Conflict with Europe’s Antimicrobial Resistance Ambitions?

Mon, Nov 9, 2026 · 4:45–5:45 PM CET Hall L, Level 1, Austria Center Vienna

About this session

The Joint Clinical Assessment (JCA), introduced under the EU HTA Regulation, focuses on patient level efficacy and safety of new health technologies. This debate will explore whether this narrow focus is at odds with the concept of Whole Health, particularly with the backdrop of EU Antimicrobial Resistance (AMR) priorities.

Speakers